Symbicordâ Turbuhaler 80:4.5 _g/dose. 160:4.5 _g/dose Inhaler
PDF Leaflet Revision Date: 25 January 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of asthma and COPD.
Dosage (summary)
Adults: 1-2 inhalations twice daily; up to 12 inhalations/day as needed.
Onset of Action / Duration
Onset: 1-3 mins, Duration: 12 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not established; contraindicated in breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- Beta-adrenergic blockers
- QT prolonging agents
Contraindications
- Hypersensitivity to components
- Children <12 years
Common side effects
- Palpitations
- Tremor
- Headache
- Cough
- Hoarseness
Counselling Points
- Rinse mouth after use
- Use as prescribed
- Monitor for worsening symptoms
Serious warnings
- Risk of pneumonia in COPD
- Adrenal insufficiency risk in steroid transfer
Important Disclaimer
The Symbicordâ Turbuhaler 80:4.5 _g/dose. 160:4.5 _g/dose Inhaler professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
